Scinai Immunotherapeutics (SCNI) EBITDA (2014 - 2026)

Scinai Immunotherapeutics (SCNI) has 13 years of EBITDA data on file, last reported at -$2.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 57.33% year-over-year to -$2.5 million; the trailing twelve-month figure through Mar 2026 stood at -$8.5 million (up 30.01% YoY), and the FY2025 full-year result was -$9.7 million, down 12.82% from the prior year.
• EBITDA eased to -$2.5 million in Q1 2026, from -$2.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $3.3 million in Q2 2022 to a low of -$19.1 million in Q4 2022.
• A 5-year average of -$2.0 million and a median of -$2.1 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 221.84% in 2023 and tumbled 326.71% in 2024, its largest moves.
• Tracing SCNI's EBITDA over 5 years: stood at -$19.1 million in 2022, then jumped by 90.46% to -$1.8 million in 2023, then fell by 24.14% to -$2.3 million in 2024, then climbed by 3.0% to -$2.2 million in 2025, then fell by 12.39% to -$2.5 million in 2026.
• Business Quant data shows SCNI's EBITDA at -$2.5 million in Q1 2026, -$2.2 million in Q2 2025, and -$1.6 million in Q1 2025.